James Edgemond Sells 7,782 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

by · The Cerbat Gem

United Therapeutics Co. (NASDAQ:UTHR – Get Free Report) CFO James Edgemond sold 7,782 shares of the firm’s stock in a transaction dated Monday, October 21st. The shares were sold at an average price of $366.99, for a total value of $2,855,916.18. Following the transaction, the chief financial officer now owns 6,426 shares of the company’s stock, valued at approximately $2,358,277.74. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

James Edgemond also recently made the following trade(s):

  • On Monday, October 14th, James Edgemond sold 7,792 shares of United Therapeutics stock. The shares were sold at an average price of $355.88, for a total value of $2,773,016.96.
  • On Monday, October 7th, James Edgemond sold 7,794 shares of United Therapeutics stock. The shares were sold at an average price of $355.54, for a total value of $2,771,078.76.
  • On Monday, September 30th, James Edgemond sold 7,792 shares of United Therapeutics stock. The shares were sold at an average price of $358.62, for a total value of $2,794,367.04.
  • On Monday, September 23rd, James Edgemond sold 7,796 shares of United Therapeutics stock. The shares were sold at an average price of $354.04, for a total value of $2,760,095.84.
  • On Monday, September 9th, James Edgemond sold 7,802 shares of United Therapeutics stock. The shares were sold at an average price of $345.41, for a total value of $2,694,888.82.
  • On Tuesday, September 3rd, James Edgemond sold 7,785 shares of United Therapeutics stock. The stock was sold at an average price of $362.37, for a total value of $2,821,050.45.

United Therapeutics Trading Down 0.1 %

Shares of United Therapeutics stock traded down $0.34 on Tuesday, hitting $370.26. 176,644 shares of the company traded hands, compared to its average volume of 468,383. The stock’s 50 day moving average price is $351.40 and its 200-day moving average price is $309.96. The company has a current ratio of 4.35, a quick ratio of 4.18 and a debt-to-equity ratio of 0.02. United Therapeutics Co. has a 52 week low of $208.62 and a 52 week high of $377.03. The company has a market cap of $16.47 billion, a PE ratio of 16.94, a PEG ratio of 1.34 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported $5.85 earnings per share for the quarter, missing the consensus estimate of $6.33 by ($0.48). The company had revenue of $714.90 million for the quarter, compared to the consensus estimate of $691.87 million. United Therapeutics had a net margin of 40.87% and a return on equity of 18.82%. The business’s revenue was up 19.8% on a year-over-year basis. During the same period in the prior year, the firm posted $5.24 EPS. Equities research analysts predict that United Therapeutics Co. will post 24.72 EPS for the current year.

Analysts Set New Price Targets

UTHR has been the subject of several recent research reports. Morgan Stanley lowered United Therapeutics from an “overweight” rating to an “equal weight” rating and lifted their price target for the stock from $310.00 to $321.00 in a research report on Thursday, July 11th. Jefferies Financial Group lifted their price target on United Therapeutics from $315.00 to $432.00 and gave the stock a “buy” rating in a research report on Monday, September 23rd. LADENBURG THALM/SH SH lowered United Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 1st. HC Wainwright reiterated a “buy” rating and issued a $400.00 price target on shares of United Therapeutics in a research report on Thursday, August 1st. Finally, Wells Fargo & Company raised their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 20th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $361.33.

Read Our Latest Report on UTHR

Hedge Funds Weigh In On United Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Meiji Yasuda Asset Management Co Ltd. grew its holdings in shares of United Therapeutics by 1.6% during the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,047 shares of the biotechnology company’s stock valued at $652,000 after buying an additional 33 shares during the last quarter. Toronto Dominion Bank lifted its position in United Therapeutics by 0.8% during the second quarter. Toronto Dominion Bank now owns 4,525 shares of the biotechnology company’s stock valued at $1,441,000 after purchasing an additional 37 shares during the period. ClariVest Asset Management LLC lifted its position in United Therapeutics by 120.0% during the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 42 shares during the period. Benjamin F. Edwards & Company Inc. lifted its position in United Therapeutics by 14.0% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 343 shares of the biotechnology company’s stock valued at $109,000 after purchasing an additional 42 shares during the period. Finally, First Citizens Bank & Trust Co. lifted its position in United Therapeutics by 1.8% during the third quarter. First Citizens Bank & Trust Co. now owns 2,681 shares of the biotechnology company’s stock valued at $961,000 after purchasing an additional 48 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Featured Stories